REKAH PHARMA (Israel) Today


ILA 2,162  78.00  3.74%   

Market Performance
2 of 100
Odds Of Distress
Less than 1
REKAH PHARMA is trading at 2162.00 as of the 19th of August 2022, a 3.74 percent up since the beginning of the trading day. The stock's open price was 2084.0. REKAH PHARMA has a very small chance of experiencing financial distress in the next few years but had a somewhat weak performance during the last 90 days. Equity ratings for REKAH PHARMA IND are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 20th of July 2022 and ending today, the 19th of August 2022. Click here to learn more.
Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of prescription and OTC drugs, dermo-cosmetics, vitamins, and nutritional supplements in Israel. The company offers steroid tablets antibiotics, including penicillin and cephalosporin drops and ointments to treat allergies, infections, and dryness of the eyes dermatological preparations baby products and vitamins and nutritional supplements. The company has 11.41 M outstanding shares. More on REKAH PHARMA IND
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

REKAH PHARMA Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. REKAH PHARMA's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding REKAH PHARMA or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
REKAH PHARMA IND is unlikely to experience financial distress in the next 2 years
About 30.0% of the company outstanding shares are owned by corporate insiders
Deputy CEOYuval Elgrably
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of REKAH PHARMA's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong SellOvervalued
REKAH PHARMA IND (REKA) is traded on Tel Aviv Stock Exchange in Israel and employs 399 people. The company currently falls under 'Large-Cap' category with current market capitalization of 24.68 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate REKAH PHARMA's market, we take the total number of its shares issued and multiply it by REKAH PHARMA's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. REKAH PHARMA IND operates under Healthcare sector and is part of Drug Manufacturers—Specialty & Generic industry. The entity has 11.41 M outstanding shares. REKAH PHARMA IND has accumulated about 21.64 M in cash with 23.14 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.9.
Check REKAH PHARMA Probability Of Bankruptcy
REKAH PHARMA IND has a total of 11.41 Million outstanding shares. REKAH PHARMA has noticeable amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.

Ownership Allocation (%)

Check REKAH Ownership Details

REKAH Stock Price Odds Analysis

What are REKAH PHARMA's target price odds to finish over the current price? Depending on a normal probability distribution, the odds of REKAH PHARMA jumping above the current price in 90 days from now is about 5.42%. The REKAH PHARMA IND probability density function shows the probability of REKAH PHARMA stock to fall within a particular range of prices over 90 days. Assuming the 90 days trading horizon REKAH PHARMA IND has a beta of -0.2689 indicating as returns on benchmark increase, returns on holding REKAH PHARMA are expected to decrease at a much lower rate. During the bear market, however, REKAH PHARMA IND is likely to outperform the market. Additionally, the company has an alpha of 0.0624, implying that it can generate a 0.0624 percent excess return over DOW after adjusting for the inherited market risk (beta).
  Odds Below 2162.0HorizonTargetOdds Above 2162.0
94.51%90 days
Based on a normal probability distribution, the odds of REKAH PHARMA to move above the current price in 90 days from now is about 5.42 (This REKAH PHARMA IND probability density function shows the probability of REKAH Stock to fall within a particular range of prices over 90 days) .


Investors will always prefer to have the highest possible return on investment while minimizing volatility. REKAH PHARMA market risk premium is the additional return an investor will receive from holding REKAH PHARMA long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in REKAH PHARMA. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although REKAH PHARMA's alpha and beta are two of the key measurements used to evaluate REKAH PHARMA's performance over the market, the standard measures of volatility play an important role as well.

REKAH Stock Against Markets

Picking the right benchmark for REKAH PHARMA stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in REKAH PHARMA stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for REKAH PHARMA is critical whether you are bullish or bearish towards REKAH PHARMA IND at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in REKAH PHARMA without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Sync Your Broker Now


Sync Your Broker

Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
All  Next Launch Module

REKAH PHARMA Corporate Directors

REKAH PHARMA corporate directors refer to members of a REKAH PHARMA board of directors. The board of directors generally takes responsibility for the REKAH PHARMA's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of REKAH PHARMA's board members must vote for the resolution. The REKAH PHARMA board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Amiram Boehm - DirectorProfile
Michael Avnimelech - External DirectorProfile
Ilan Horesh - External DirectorProfile
Ehood Nisan - External DirectorProfile


You need to understand the risk of investing before taking a position in REKAH PHARMA. The danger of trading REKAH PHARMA IND is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of REKAH PHARMA is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than REKAH PHARMA. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile REKAH PHARMA IND is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additionally, take a look at Your Equity Center. Note that the REKAH PHARMA IND information on this page should be used as a complementary analysis to other REKAH PHARMA's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Focused Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Complementary Tools for REKAH Stock analysis

When running REKAH PHARMA IND price analysis, check to measure REKAH PHARMA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy REKAH PHARMA is operating at the current time. Most of REKAH PHARMA's value examination focuses on studying past and present price action to predict the probability of REKAH PHARMA's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move REKAH PHARMA's price. Additionally, you may evaluate how the addition of REKAH PHARMA to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Global Correlations
Find global opportunities by holding instruments from different markets
Please note, there is a significant difference between REKAH PHARMA's value and its price as these two are different measures arrived at by different means. Investors typically determine REKAH PHARMA value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, REKAH PHARMA's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.